Healthy Volunteers Clinical Trial
Official title:
Reliability Intra and Inter-evaluators and Physiological Analysis of an Isometric Test of Localized Muscular Fatigue
Verified date | March 2019 |
Source | Universidade Estadual Paulista Júlio de Mesquita Filho |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Introduction: The isokinetic dynamometer, considered a gold standard tool for physical
evaluation, is widely used in studies that aim to evaluate the reliability and
reproducibility of localized muscular endurance (LME) tests. However, such tests may not
represent full LME by fixing time or number of replicates. Therefore, it is relevant to
construct a test that respects the actual capacity of each subject to withstand fatigue and
to submit such a test to validation, as well as to physiological analysis.
Research objectives: To assess the inter- and intra-rater reliability of a localized
isometric endurance test (IET) on the isokinetic dynamometer and to establish the metabolic
demand required during the test.
Design: Reliability study with test-reteste dynamic.
Participants and Setting: After fulfilling the eligibility criteria, eighty-eight male
participants will participate in the study.
Procedure: In phase 1 forty-eight participants will submitted to reliability of the IET
within three sessions: familiarization session, test session and retest sessio. In phase 2
forty participants will be submitted the metabolic demand required during the IET will be
analyzed by means of gas analysis, blood lactat concetrate and muscular activation
percentage.
Intervention: isometric endurance teste.
Measurements: The measurements include time of execution of test, work of test, physiological
and psychological outcomes.
Status | Completed |
Enrollment | 80 |
Est. completion date | September 1, 2018 |
Est. primary completion date | July 1, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 30 Years |
Eligibility |
Inclusion Criteria: - Healthy (self-report); - Male gender; - Aged between 18-30 years; - Agreement to participate through signed statement of informed Exclusion Criteria: - Being sick; - Training or physical activity at least 24 hours priot to the application test; - Being influenced in some way by test information; - Do not understand the test; - Inflammatory process; - Cardiovascular disease; - Episode of musculo-tendinous or osteoarticular lesion in the lower limbs and/or spine in the last seix months; |
Country | Name | City | State |
---|---|---|---|
Brazil | Larissa Rodrigues Larissa Rodrigues Souto | Presidente Prudente | SP |
Brazil | Larissa Rodrigues Souto | Presidente Prudente | SP |
Lead Sponsor | Collaborator |
---|---|
Universidade Estadual Paulista Júlio de Mesquita Filho | Fundação de Amparo à Pesquisa do Estado de São Paulo |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The time of execution of the test | This outcome will be assessed in seconds during execution of the test | 45 seconds after the beginning of the test | |
Secondary | The work of the test | This outcome will be assessed in Newton.meter (N.m) during execution of the test | day 2 and day 7 | |
Secondary | Oxygen consumption - gas analysis | Gas analysis will be measured during the test and after seven minutes of the same (VO2000, MedGraphics, Minnesota, USA). | Second phase during all the test | |
Secondary | Blood lactate concentration | The blood lactate concentration will be collected in the 10 minutes of rest before the test and immediately after the test and in the third, fifth and seven minutes after the test | Second phase, 10 minutes of rest before the test and immediately after the test and in the third, fifth and seven minutes after the test | |
Secondary | Muscular activation percentage | The muscular activation percentage will be assessed by means of twitch interpolation technique ( current generator - Quark) | Day 2 | |
Secondary | Psychological Questionnaire | Participants will be instructed to mark with a dash, on a 10 centimeters analogical visual scale in between two extremes, in which zero means "non-existent" and 10 "very intense" to each classification | Day 2 and day 7 | |
Secondary | Work Ability Index Questionnaire | This questionnaire consists in seven indicators, which provide a score between seven and 49, in which the highest the scores the better. These indicators evaluate occupational wellness, providing subjective estimation about work capacity, including the ability to perform work tasks in relation to demands, health and mental resources | Day 1 | |
Secondary | Perceived Stress Scale | This scale is intended to document participants' related stress on the previous month. Items evaluate the degree to which people find life unpredictable, uncontrollable or overloaded. This scale evaluates overall beliefs about perceived stress, without the providence of any specific event lists in life to the subjects, allowing these scores not to be biased by the event content or difference of previous life experience | Day 1 | |
Secondary | Bergen Insomnia Scale | This scale is intended to evaluate participants' sleep and tiredness, which consists in six questions about sleep issues in the previous month. Questions are about (1) problems initiating sleep, (2) awakening from sleep, (3) early morning awakening, (4) not feeling adequately rested, (5) experiencing daytime impairment and (6) being dissatisfied with sleep. To each question participants will answer on a zero to seven days a week scale. The quantity of days will be calculated based on the average of the answers to these six questions, in order to obtain an overall sleep problems score | Day 1 | |
Secondary | Need for Recovery Scale | This is an 11 item scale which aims to evaluate work fatigue symptoms, related to a series of emotional, cognitive and behavioral aspects characterized as temporary overload feelings, irritability, social seclusion, lack of energy for new efforts and performance reduction | Day 7 | |
Secondary | Borg Scale | Participants' physical effort perception will also be measured by the Borg Scale, which will be used to correlate with heart rate values. After the completion of IET participants willl answer the following question: "How much exertion did you experience during the test? ". This scale has 15 possible answers, ranging from six to 20, represented respectively from "not exertion at all" to "maximal exertion". | Day 7 | |
Secondary | Borg CR10 Scale | Participants' physical effort perception will be measured by The Borg CR10 Scale. After the IET application participants will answer the following question: "How much exertion did you experience during the test? ". This scale has 16 possible answers which vary from zero to 10 represented respectively from no effort to maximum effort. | Day 7 | |
Secondary | Effort Perception Scale | The effort perception will be evaluated by the Effort Perception Scale, with values between 0 and 10, 0 being correspondent to no effort at all (rest) and 10, to maximum effort | Day 1, day 2 and day 7 | |
Secondary | Recovery Perception Scale | The perceived recovery of the dominant lower limb will be assessed by means of the Effort Perception Scale, which consists of a 10-point Likert Scale, in which 1 means no recovery and 10, completely recovered | Day 1, day 2 and day 7 | |
Secondary | Heart Rate | The heart rate caption will take place using a cardio frequency meter (Polar electro, Oy Kempele, Finland - V800 model) | Day 2 and day 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |